Clinical Trials
23 trialsStudy of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer
Ruijin Hospital
UNITO-001
University of Turin, Italy
MiST
University of Leicester
A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
Sichuan Cancer Hospital and Research Institute
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
Zhejiang Cancer Hospital
t
Peking Union Medical College Hospital
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
POLO
Seoul National University Hospital
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Peking Union Medical College Hospital
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients
Sun Yat-sen University
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
Niraparib Combined With Radiotherapy in rGBM
Tianjin Huanhu Hospital
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
Massachusetts General Hospital
ANNIE
Sun Yat-sen University
AVANIRA3
Jiangsu Cancer Institute & Hospital
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
Hunan Cancer Hospital